The Natural Product Eugenol Is an Inhibitor of the Ebola Virus In Vitro
Since the 2014 Ebola virus (EBOV) outbreak in West Africa there has been considerable effort towards developing drugs to treat Ebola virus disease and yet to date there is no FDA approved treatment. This is important as at the time of writing this manuscript there is an ongoing outbreak in the Democratic Republic of the Congo which has killed over 1000.
We have evaluated a small number of natural products, some of which had shown antiviral activity against other pathogens. This is exemplified with eugenol, which is found in high concentrations in multiple essential oils, and has shown antiviral activity against feline calicivirus, tomato yellow leaf curl virus, Influenza A virus, Herpes Simplex virus type 1 and 2, and four airborne phages.
Four compounds possessed EC50 values less than or equal to 11 μM. Of these, eugenol, had an EC50 of 1.3 μM against EBOV and is present in several plants including clove, cinnamon, basil and bay. Eugenol is much smaller and structurally unlike any compound that has been previously identified as an inhibitor of EBOV, therefore it may provide new mechanistic insights.
This compound is readily accessible in bulk quantities, is inexpensive, and has a long history of human consumption, which endorses the idea for further assessment as an antiviral therapeutic. This work also suggests that a more exhaustive assessment of natural product libraries against EBOV and other viruses is warranted to improve our ability to identify compounds that are so distinct from FDA approved drugs.
Key wordsantiviral drug discovery ebola eugenol p-anisaldehyde
Acknowledgments and Disclosures
Ms. Kimberley M. Zorn, Dr. Mary A. Lingerfelt and Dr. Alex M. Clark, are kindly acknowledged for their assistance. T.L., and S.E. work for Collaborations Pharmaceuticals, Inc.
SE kindly acknowledges NIH funding: R21TR001718 from NCATS (PI – Sean Ekins).
- 8.Kaiser R. Meaningful scents around the world. Zurich: Wiley, VCH; 2006.Google Scholar
- 17.CDC. 2014 ebola outbreak in West Africa - case counts 2016. Available from: http://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/case-counts.html. Accessed 3 may 2019.
- 20.Madrid PB, Chopra S, Manger ID, Gilfillan L, Keepers TR, Shurtleff AC, Green CE, Iyer LV, Dilks HH, Davey RA, Kolokoltsov AA, Carrion R, Jr., Patterson JL, Bavari S, Panchal RG, Warren TK, Wells JB, Moos WH, Burke RL, Tanga MJ. A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PLoS One 2013;8(4):e60579.PubMedPubMedCentralCrossRefGoogle Scholar
- 35.Ekins S, Lingerfelt MA, Comer JE, Freiberg AN, Mirsalis JC, O’Loughlin K, et al. Efficacy of Tilorone Dihydrochloride against Ebola virus infection. Antimicrob Agents Chemother. 2017;In Press;62.Google Scholar
- 36.Bai JPF, Hsu CW. Drug repurposing for Ebola virus disease: principles of consideration and the animal rule. J Pharm Sci. 2018. https://doi.org/10.1016/j.xphs.2018.1009.1010 Epub ahead of print.
- 38.Andrade-Ochoa S, Nevarez-Moorillon GV, Sanchez-Torres LE, Villanueva-Garcia M, Sanchez-Ramirez BE, Rodriguez-Valdez LM, et al. Quantitative structure-activity relationship of molecules constituent of different essential oils with antimycobacterial activity against Mycobacterium tuberculosis and Mycobacterium bovis. BMC Complement Altern Med. 2015;15:332.Google Scholar
- 40.Sneader W. Drug discovery a history. Cheppenham: Wiley; 2005.Google Scholar
- 70.Young DW. Considerations related to small-molecule screening collections. In: Bittker JA, Ross NT, editors. High throughput screening methods: evolution and refinement. Cambridge: The Royal Society of Chemistry; 2017. p. 16–36.Google Scholar